Albert Vilella, PhD.
@albertvilella.bsky.social
Bioinformatics Scientist / Next Generation Sequencing, Single Cell and Spatial Biology, Next Generation Proteomics, Liquid Biopsy, SynBio, Compute Acceleration in biotech // http://albertvilella.substack.com
@jaredwhitlock.bsky.social writes for @endpts.com on Hepta Bio:
"Former Illumina, Grail and Google employees are adapting the same blood-based DNA technology used in cancer and prenatal screening to diagnose chronic conditions like liver disease.
"Former Illumina, Grail and Google employees are adapting the same blood-based DNA technology used in cancer and prenatal screening to diagnose chronic conditions like liver disease.
November 25, 2025 at 1:49 PM
@jaredwhitlock.bsky.social writes for @endpts.com on Hepta Bio:
"Former Illumina, Grail and Google employees are adapting the same blood-based DNA technology used in cancer and prenatal screening to diagnose chronic conditions like liver disease.
"Former Illumina, Grail and Google employees are adapting the same blood-based DNA technology used in cancer and prenatal screening to diagnose chronic conditions like liver disease.
@semianalysis.substack.com.web.brid.gy Dylan Patel on the AMD ROCm PyTorch support.
November 25, 2025 at 11:21 AM
@semianalysis.substack.com.web.brid.gy Dylan Patel on the AMD ROCm PyTorch support.
#FlagshipPioneering, an innovation company based in MA, USA, and GSK have expanded their framework via five feasibility agreements with #ProFoundTherapeutics and #QuotientTherapeutics to discover targets and approaches in COPD, IPF and MASH,
November 24, 2025 at 12:58 PM
#FlagshipPioneering, an innovation company based in MA, USA, and GSK have expanded their framework via five feasibility agreements with #ProFoundTherapeutics and #QuotientTherapeutics to discover targets and approaches in COPD, IPF and MASH,
#MitoRxTherapeutics, a biotech based in the UK and led by CEO Jon Rees raised a £5.5 million (USD ≈ 7.2 m) pre-Series A round. The company develops mitochondrial-targeted small molecules for obesity
November 24, 2025 at 12:50 PM
#MitoRxTherapeutics, a biotech based in the UK and led by CEO Jon Rees raised a £5.5 million (USD ≈ 7.2 m) pre-Series A round. The company develops mitochondrial-targeted small molecules for obesity
#Profluent, a biotech based in CA, USA and led by CEO Ali Madani raised a $106 million financing round. The company develops large-scale frontier AI models for programmable biology (protein design, genome editors, antibodies, enzymes)
November 24, 2025 at 12:47 PM
#Profluent, a biotech based in CA, USA and led by CEO Ali Madani raised a $106 million financing round. The company develops large-scale frontier AI models for programmable biology (protein design, genome editors, antibodies, enzymes)
selvi ergin on the Cambridge UK biotech hub
November 24, 2025 at 8:55 AM
selvi ergin on the Cambridge UK biotech hub
Astrazeneca US onshoring rare diseases
November 23, 2025 at 9:16 PM
Astrazeneca US onshoring rare diseases
2024 was the worst for growth when looking at the Russell 2000, 2025 slightly positive, 2026 in full recovery swing. #tech #biotech #smallcaps
Russell 2000 EPS growth forecast eases to just 48% for CY 2026 $IWM GS
November 23, 2025 at 3:31 PM
2024 was the worst for growth when looking at the Russell 2000, 2025 slightly positive, 2026 in full recovery swing. #tech #biotech #smallcaps
Michael Burry on Nvidia $NVDA financials
November 23, 2025 at 3:16 PM
Michael Burry on Nvidia $NVDA financials
Example of bio::levenshtein in Rust mentioned in the post by Ash #Bioinformatics #DNA
November 23, 2025 at 7:35 AM
Example of bio::levenshtein in Rust mentioned in the post by Ash #Bioinformatics #DNA
@ashvardanian running stringzilla on latest generation CPUs versus Nvidia $NVDA B200 GPUs showing how narrow the advantage is for GPUs outside of low precision matrix multiplication
November 23, 2025 at 7:32 AM
@ashvardanian running stringzilla on latest generation CPUs versus Nvidia $NVDA B200 GPUs showing how narrow the advantage is for GPUs outside of low precision matrix multiplication
@eliadjosephson on the Abbott / Exact Sciences M&A
November 22, 2025 at 12:12 PM
@eliadjosephson on the Abbott / Exact Sciences M&A
Howard Yu on the changing environment for Chinese academics who used to do a BIA (Been in America) stint in their career, but might be rethinking it now.
November 22, 2025 at 12:04 PM
Howard Yu on the changing environment for Chinese academics who used to do a BIA (Been in America) stint in their career, but might be rethinking it now.
Ruby Gadelrab on the acquisition
November 22, 2025 at 6:40 AM
Ruby Gadelrab on the acquisition
@iiseymour.bsky.social on the new Oxford @nanoporetech.com Dorado release
November 21, 2025 at 2:03 PM
@iiseymour.bsky.social on the new Oxford @nanoporetech.com Dorado release
Abbott acquires Exact Sciences for $23B, and Freenome and Roche news open.substack.com/pub/albertvi...
Abbott acquires Exact Sciences for $23B, and Freenome and Roche news
An update on the Liquid Biopsy, MCED, Cancer Diagnostics landscape
open.substack.com
November 21, 2025 at 1:41 PM
Abbott acquires Exact Sciences for $23B, and Freenome and Roche news open.substack.com/pub/albertvi...
@eromanovskaya on the new n=1 drugs approval by the FDA
November 20, 2025 at 6:47 PM
@eromanovskaya on the new n=1 drugs approval by the FDA
@10xgenomics.bsky.social and Oxford @nanoporetech.com for the mouse hypocampus
We are excited to announce our most recent preprint “Single-cell long-read sequencing of the experience-induced transcriptome” (www.biorxiv.org/content/10.1...) led by @sheridan in collaboration with Richard Huganir. A few highlights:
Single-cell long-read sequencing of the experience-induced transcriptome
Neural activity drives transcriptional events that are critical for learning. Activity-induced transcript isoform expression and alternative splicing are cell-type specific events typically obscured b...
www.biorxiv.org
November 20, 2025 at 6:33 PM
@10xgenomics.bsky.social and Oxford @nanoporetech.com for the mouse hypocampus
It's confirmed. Abbott will acquire Exact Sciences $EXAS for $23B
November 20, 2025 at 6:30 PM
It's confirmed. Abbott will acquire Exact Sciences $EXAS for $23B
DNAe wants to offer a rapid cartridge-based sequencing method to improve diagnosis of infectious disease and cancer
November 20, 2025 at 6:38 AM
DNAe wants to offer a rapid cartridge-based sequencing method to improve diagnosis of infectious disease and cancer
$EXAS Exact sciences stock bounced 24% today on the rumours of a possible M&A premium. Read more about Exact on my blog, link in bio.
November 20, 2025 at 6:23 AM
$EXAS Exact sciences stock bounced 24% today on the rumours of a possible M&A premium. Read more about Exact on my blog, link in bio.
@heikohotz.bsky.social on the Google Gemini TPU play
November 20, 2025 at 6:20 AM
@heikohotz.bsky.social on the Google Gemini TPU play
Abbott Laboratories is nearing a potential acquisition of Exact Sciences Corp, in what would be its largest deal in nearly a decade, people familiar with the matter said. www.bloomberg.com/news/article...
Abbott Nears Deal for Cancer Test Maker Exact Sciences
Abbott Laboratories is nearing a potential acquisition of medical-testing company Exact Sciences Corp., in what would be its largest deal in nearly a decade, people familiar with the matter said.
www.bloomberg.com
November 19, 2025 at 8:24 PM
Abbott Laboratories is nearing a potential acquisition of Exact Sciences Corp, in what would be its largest deal in nearly a decade, people familiar with the matter said. www.bloomberg.com/news/article...
Nasdaq volatility as high as during the Liberation Day storm.
$VXN Nasdaq 100 volatility - highest since April 22nd
November 19, 2025 at 2:55 PM
Nasdaq volatility as high as during the Liberation Day storm.